(2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-[[(3S)-1-[5-(trifluoromethyl)pyridin-2-yl]pyrrolidin-3-yl]amino]purin-9-yl]oxolane-3,4-diol

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: (2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-[[(3S)-1-[5-(trifluoromethyl)pyridin-2-yl]pyrrolidin-3-yl]amino]purin-9-yl]oxolane-3,4-diol
• 化学式: C₂₀H₂₂F₃N₇O₄
• 分子量: 481.4
• InChiKey: ITJHDXWKUVQYAF-NSDPQSHHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  34
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  142
• 氢给体数：
  4
• 氢受体数：
  13

文献信息

• Methods of treating insulin resistance syndrome and diabetes
  申请人：——

  公开号：US20030176390A1

  公开（公告）日：2003-09-18

  This invention is directed to methods of treating insulin resistance syndrome and diabetes in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound derived from adenosine and analogues thereof, or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable prodrug thereof, an N-oxide thereof, a hydrate thereof or a solvate thereof, or a pharmaceutical composition comprising such compound.

  本发明涉及治疗胰岛素抵抗综合征和糖尿病的方法，包括向需要治疗的患者施用从腺苷和其类似物衍生的化合物的药效量，或其药用盐、药用前药、N-氧化物、水合物或溶剂化合物，或包含该化合物的药物组合物。
• COMPOUNDS HAVING ANTIHYPERTENSIVE, CARDIOPROTECTIVE, ANTI-ISCHEMIC AND ANTILIPOLYTIC PROPERTIES
  申请人：Aventis Pharmaceuticals Products Inc.

  公开号：EP0912520B1

  公开（公告）日：2003-05-07
• ADENOSINE ANALOGUES FOR THE TREATMENT OF THE INSULIN RESISTANCE SYNDROME AND DIABETES
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1404338A1

  公开（公告）日：2004-04-07
• [EN] ADENOSINE ANALOGUES FOR THE TREATMENT OF THE INSULIN RESISTANCE SYNDROME AND DIABETES<br/>[FR] ANALOGUES DE L'ADENOSINE POUR LE TRAITEMENT DU SYNDROME DE RESISTANCE A L'INSULINE ET DU DIABETE
  申请人：AVENTIS PHARMA GMBH

  公开号：WO2002092093A1

  公开（公告）日：2002-11-21

  The invention relates to the use of adenosine compounds described by formula (I) and certain derivatives thereof for producing a medicine for the treatment of the insulin resistance syndrome and diabetes. In formula (I), K is N, NO, or CH; Q is CH2 or O; R6 is hydrogen, alkyl, allyl, 2-methallyl, 2-butenyl, or cycloalkyl; X is (a) or (b); E is O or S; Y is e.g. hydrogen, alkyl, aralkyl, aryl; n and p are independently 0, 1, 2 or 3 provided that n + p is at least 1; T is e.g. hydrogen, alkyl, acyl, thioacyl, halo, carboxyl; R1, R2 and R3 are independently H, alkyl, or cycloalkyl; A is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or OR'; B is hydrogen, alkyl, hydroxyalkyl, alkoxyalkyl, or OR'; R' and R' are e.g independently hydrogen, alkyl, aralkyl or carbamoyl.